Clinical and Histopathological Predictors of Disease Progression in Stage II Cutaneous Melanoma.

Twenty-one of 103 (20.4%) patients recurred, of whom 15/21 (71.4%) showed disease progression to stage IV disease.

Histopathological evidence of ulceration and the mitotic rate did not show a significant association with melanoma progression.

Breslow thickness was also associated with a reduced time from melanoma diagnosis to recurrence per each unit increase (mm) (p = 0.032) and with shorter disease-free survival probability (HR: 1.47; 95% CI: 1.05-2.06; p = 0.025).